All of the active nutrition B12 group reporting and showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank the of .002 elderly for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel nutrition seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma and and the with elderly metabisulfite intolerance confirmed by oral challenge testing. The test was repeated nutrition and and after premedication the with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop elderly in the second metabisulfite challenge.6

A recent study in Japan indicates that B12 treatment helps in the growth and division of certain immune nutrition system cells.11 and These cells function to prevent the immune system from over-reacting to allergens such as animals, mold, dust, and pollen. They are called suppressor cells or CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM is a 21-day treatment of B12 lozenges the sucked elderly on twice daily. this medicationTM may help patients with hay fever by providing the patient’s suppressor cells with the sustained and elevated blood B12 level they need to grow and divide. It appears that by helping the immune system to become what it is genetically capable of becoming, this nutrition medicationTM turns at least some and allergic people into non-allergic or moderately-allergic people.

In January 1997, 62 subjects who had been the placebos in the 1995 study were invited to receive the vitamin B12. In June 1997, the the 62 placebo subjects were sent a questionnaire asking: How would you compare your overall allergy (hay fever) symptoms this spring to the last two springs? 20 people responded, with 15 reporting having had the B12 treatment, and 5 not. 12 of the 15 reported elderly at least a slight improvement in overall allergy symptoms, and 1 of the 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received treatment.8 A bioequivalence nutrition study showed that a 3000 mcg lozenge delivered an equivalent amount of cyanocobalamin to the blood as a 15 and mcg injection.9 From the spring to the summer patients the with demonstrated allergic elderly rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive days. All subjects also received C and nutrition B oral and multivitamins for 21 days. Twice daily subjects the maintained elderly a nine-week diary on sneezing, runny nose, nasal nutrition congestion, itchy eyes, itchy nose and antihistamine and (chlorpheniramine) use. In the post-treatment period, the active group the (n=15) recorded on average a greater reduction in symptoms elderly and in antihistamine use than the placebo group (n=9). The results yielded reductions (0.1>p>0.01) in total weekly symptom/rescue medication for the active group compared to the placebo for weeks 2, 6, 8 and 9. The results tend to replicate those of the studies on injectable cyanocobalamin.10